Lantheus Holdings, Inc. (LNTH) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 335.68M USD | Liabilities, Current |
| Cash and equivalents | 593.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 352.89M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 57.55M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $335.68M | $593.30M | (m) | $352.89M | $57.55M | (m) |
| 2026-03-31 | (m) | $333.17M | $498.58M | (m) | $355.67M | $61.34M | (m) |
| 2025-12-31 | (m) | $333.42M | $359.12M | (m) | $358.64M | $64.67M | (m) |
| 2025-09-30 | (m) | $346.84M | $382.01M | (m) | $351.38M | $62.04M | (m) |
| 2025-06-30 | (m) | $280.13M | $695.57M | (m) | $336.58M | $62.16M | (m) |
| 2025-03-31 | (m) | $248.00M | $938.53M | (m) | $348.75M | $69.13M | (m) |
| 2024-12-31 | (m) | $240.53M | $912.81M | (m) | $321.26M | $68.03M | (m) |
| 2024-09-30 | (m) | $784.08M | $866.39M | (m) | $329.34M | $70.83M | (m) |
| 2024-06-30 | (m) | $263.29M | $757.02M | (m) | $372.29M | $70.52M | (m) |
| 2024-03-31 | (m) | $237.20M | $718.28M | (m) | $337.39M | $69.76M | (m) |
| 2023-12-31 | (m) | $187.35M | $713.66M | (m) | $284.29M | $64.03M | (m) |
| 2023-09-30 | (m) | $176.60M | $614.13M | (m) | $259.20M | $56.46M | (m) |
| 2023-06-30 | (m) | $154.04M | $414.08M | (m) | $256.28M | $51.80M | (m) |
| 2023-03-31 | (m) | $276.39M | $470.86M | (m) | $242.11M | $42.16M | (m) |
| 2022-12-31 | (m) | $247.70M | $415.65M | (m) | $213.40M | $35.48M | (m) |
| 2022-09-30 | (m) | $235.98M | $257.26M | (m) | $197.28M | $34.79M | (m) |
| 2022-06-30 | (m) | $219.02M | $171.43M | (m) | $187.05M | $33.96M | (m) |
| 2022-03-31 | (m) | $177.66M | $105.36M | (m) | $172.28M | $34.25M | (m) |
| 2021-12-31 | (m) | $90.50M | $98.51M | (m) | $89.34M | $35.13M | (m) |
| 2021-09-30 | (m) | $76.90M | $91.47M | (m) | $64.05M | $33.95M | (m) |
| 2021-06-30 | (m) | $73.83M | $91.50M | (m) | $54.89M | $31.72M | (m) |
| 2021-03-31 | (m) | $64.59M | $68.86M | (m) | $58.99M | $30.36M | (m) |
| 2020-12-31 | (m) | $80.50M | $79.61M | (m) | $54.00M | $35.74M | (m) |
| 2020-09-30 | (m) | $82.00M | $87.99M | (m) | $49.21M | $37.62M | (m) |
| 2020-06-30 | (m) | $76.34M | $90.31M | (m) | $46.88M | $35.33M | (m) |
| 2020-03-31 | (m) | $61.96M | $95.71M | (m) | $44.88M | $30.81M | (m) |
| 2019-12-31 | (m) | $66.11M | $92.92M | (m) | $43.53M | $29.18M | (m) |
| 2019-09-30 | (m) | $59.59M | $78.06M | (m) | $40.63M | $30.60M | (m) |
| 2019-06-30 | (m) | $53.36M | $56.88M | (m) | $45.53M | $32.41M | (m) |
| 2019-03-31 | (m) | $42.77M | $112.06M | (m) | $45.02M | $32.04M | (m) |
| 2018-12-31 | (m) | $52.76M | $113.40M | (m) | $43.75M | $33.02M | (m) |
| 2018-09-30 | (m) | $54.58M | $104.58M | (m) | $47.13M | $34.57M | (m) |
| 2018-06-30 | (m) | $43.25M | $86.46M | (m) | $44.19M | $31.47M | (m) |
| 2018-03-31 | (m) | $45.40M | $73.74M | (m) | $47.83M | $32.09M | (m) |
| 2017-12-31 | (m) | $46.75M | $76.29M | (m) | $40.26M | $26.08M | (m) |
| 2017-09-30 | (m) | $46.09M | $68.08M | (m) | $41.71M | $23.03M | (m) |
| 2017-06-30 | (m) | $43.06M | $57.15M | (m) | $43.25M | $21.15M | (m) |
| 2017-03-31 | (m) | $39.13M | $40.88M | (m) | $39.93M | $19.79M | (m) |
| 2016-12-31 | (m) | $43.84M | $51.18M | (m) | $36.82M | $17.64M | (m) |
| 2016-09-30 | (m) | $39.12M | $53.20M | (m) | $34.84M | $16.06M | (m) |
| 2016-06-30 | (m) | $34.09M | $54.85M | (m) | $39.46M | $14.43M | (m) |
| 2016-03-31 | (m) | $31.48M | $38.88M | (m) | $39.90M | $15.54M | (m) |
| 2015-12-31 | (m) | $35.72M | $28.60M | (m) | $37.29M | $15.62M | (m) |
| 2015-09-30 | (m) | $34.32M | $21.92M | (m) | $39.72M | $16.58M | (m) |
| 2015-06-30 | (m) | $37.55M | $22.20M | (m) | $36.82M | $15.40M | (m) |
| 2015-03-31 | (m) | (m) | $30.74M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $48.53M | $19.74M | (m) | $41.54M | $15.58M | (m) |
| 2014-09-30 | (m) | (m) | $27.13M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $16.02M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $18.58M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $33.32M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |